<DOC>
	<DOCNO>NCT02964247</DOCNO>
	<brief_summary>The trial conduct Asia , Europe , North America South America . The aim study compare effect liraglutide 1.8 mg/day versus placebo add-on SGLT2 inhibitor without metformin glycaemic control subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>LIRA-ADD2SGLT2i - Liraglutide Versus Placebo add-on SGLT2 Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial . Male female , age 18 year old time signing informed consent . Diagnosed type 2 diabetes mellitus . HbA1c 7.09.5 % ( 5380 mmol/mol ) ( inclusive ) . Stable dose SGLT2 inhibitor monotherapy combination ( include fixeddose drug combination ) stable dose metformin ( 1500 mg , maximum tolerate dose ) least 90 day prior day screen . All medication compliance current local label . Body mass index 20 kg/m^2 . Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) . History diabetic ketoacidosis treat SGLT2 inhibitor . Renal impairment measure estimate Glomerular Filtration Rate ( eGFR ) value le 60 mL/min/1.73m^2 define Kidney Disease Improving Global Outcomes ( KDIGO ) classification use isotope dilution mass spectrometry ( IDMS ) serum creatinine measure screening . Treatment medication indication diabetes obesity state inclusion criterion within past 90 day prior day screen . However , short term insulin treatment maximum 14 day 90 day prior screen allow . Family personal history multiple endocrine neoplasia type 2 medullary thyroid carcinoma . Family define first degree relative . History presence pancreatitis ( acute chronic ) . Impaired liver function , define ALT 2.5 time upper normal limit screen . Subjects presently classify New York Heart Association ( NYHA ) Class IV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>